open access
The use of calcium channel blockers as tocolytics may adversely affect pregnancy outcomes: a randomized clinical trial
, 2
Affiliations- Department of Obstetrics and Gynecology, Amasya University, School of Medicine, Amasya, Turkey
- Department of Obstetrics and Gynecology, Kutahya Health Sciences University, Kutahya, Turkey
open access
Abstract
Objectives: To investigate the effect of calcium channel blockers in tocolytic therapy on obstetric outcomes.
Material and methods: For our study, as a retrospective case control study, data were obtained from hospital records. During 2018, there were 65 patients hospitalized with a diagnosis of preterm labor and were treated with calcium channel blockers used as tocolytics (nifedipine, nicardipine) and these patients constituted the study group. Pregnant women with systemic disease were excluded from the total of 1552 patients who were followed and who gave birth in 2018. After exclusion to equalize the samples, we chose 65 healthy pregnant women from the remaining 646 healthy pregnancies using a simple random number table and these patients formed the control group. The obstetric and neonatal results of both groups were compared.
Results: There was no difference between the groups in terms of birth week, preterm labor rate, low birth weight, and delivery type. While birth weights were significantly lower, the need for neonatal intensive care and the number of infants weighing 2500–3000 g were higher in the study group (p < 0.05). When the results of pregnancies that gave birth at term weeks and were not administered steroids were compared, the birth weight was lower and the number of infants weighing 2500–3000 g was higher in the study group.
Conclusion: The use of calcium channel blockers in pregnancy may adversely affect birth weight gain and the need for intensive care.
Abstract
Objectives: To investigate the effect of calcium channel blockers in tocolytic therapy on obstetric outcomes.
Material and methods: For our study, as a retrospective case control study, data were obtained from hospital records. During 2018, there were 65 patients hospitalized with a diagnosis of preterm labor and were treated with calcium channel blockers used as tocolytics (nifedipine, nicardipine) and these patients constituted the study group. Pregnant women with systemic disease were excluded from the total of 1552 patients who were followed and who gave birth in 2018. After exclusion to equalize the samples, we chose 65 healthy pregnant women from the remaining 646 healthy pregnancies using a simple random number table and these patients formed the control group. The obstetric and neonatal results of both groups were compared.
Results: There was no difference between the groups in terms of birth week, preterm labor rate, low birth weight, and delivery type. While birth weights were significantly lower, the need for neonatal intensive care and the number of infants weighing 2500–3000 g were higher in the study group (p < 0.05). When the results of pregnancies that gave birth at term weeks and were not administered steroids were compared, the birth weight was lower and the number of infants weighing 2500–3000 g was higher in the study group.
Conclusion: The use of calcium channel blockers in pregnancy may adversely affect birth weight gain and the need for intensive care.
Keywords
preterm labor; low birth weight; calcium channel blocker, obstetric-neonatal outcomes
About this articleTitle
The use of calcium channel blockers as tocolytics may adversely affect pregnancy outcomes: a randomized clinical trial
Journal
Issue
Article type
Research paper
Pages
820-826
Published online
2022-03-03
Page views
4166
Article views/downloads
929
DOI
Pubmed
Bibliographic record
Ginekol Pol 2022;93(10):820-826.
Keywords
preterm labor
low birth weight
calcium channel blocker
obstetric-neonatal outcomes
Authors
Aysun Tekeli Taskomur
Ozlem Erten
References (32)- Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012; 379(9832): 2162–2172.
- King JF, Grant A, Keirse MJ, et al. Beta-mimetics in preterm labour: an overview of the randomized controlled trials. Br J Obstet Gynaecol. 1988; 95(3): 211–222.
- Economy KE, Abuhamad AZ. Calcium channel blockers as tocolytics. Semin Perinatol. 2001; 25(5): 264–271.
- Papatsonis DNM, van Geijn HP, Bleker OP, et al. Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. Int J Gynaecol Obstet. 2003; 82(1): 5–10.
- Oei SG. Calcium channel blockers for tocolysis: a review of their role and safety following reports of serious adverse events. Eur J Obstet Gynecol Reprod Biol. 2006; 126(2): 137–145.
- Tshotetsi L, Dzikiti L, Hajison P, et al. Maternal factors contributing to low birth weight deliveries in Tshwane District, South Africa. PLoS One. 2019; 14(3): e0213058.
- UNICEF, WHO, Low Birthweight Estimates: Level and Trends 2000–2015, WHO Publications, Geneva, Switzerland, 2019. http://www.who.int/nutrition (05.06.2021).
- World Health Organization, World Health Assembly Global Nutrition Targets 2025: Low Birth Weight Policy Brief, World Health Organization, Geneva, Switzerland, 2014, http://www.who.int/nutrition/topics/globaltargets_stunting_policybrief. (05.06.2021).
- Albu AR, Anca AF, Horhoianu VV, et al. Predictive factors for intrauterine growth restriction. J Med Life. 2014; 7(2): 165–171.
- Sangkomkamhang U, Pattanittum P, Laopaiboon M, et al. Mode of delivery and outcomes in preterm births. J Med Assoc Thai. 2011; 94(4): 415–420.
- Galal M, Symonds I, Murray H, et al. Postterm pregnancy. Facts Views Vis Obgyn. 2012; 4(3): 175–187.
- Braun T, Weichert A, Gil HC, et al. Fetal and neonatal outcomes after term and preterm delivery following betamethasone administration. Int J Gynaecol Obstet. 2015; 130(1): 64–69.
- Sayin NC, Varol FG, Balkanli-Kaplan P, et al. Oral nifedipine maintenance therapy after acute intravenous tocolysis in preterm labor. J Perinat Med. 2004; 32(3): 220–224.
- van Vliet EOG, Nijman TAJ, Schuit E, et al. Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a multicentre, randomised controlled trial. Lancet. 2016; 387(10033): 2117–2124.
- García-Velasco JA, González González A. A prospective, randomized trial of nifedipine vs. ritodrine in threatened preterm labor. Int J Gynaecol Obstet. 1998; 61(3): 239–244.
- Abou-Ghannam G, Usta IM, Nassar AH. Indomethacin in pregnancy: applications and safety. Am J Perinatol. 2012; 29(3): 175–186.
- Ulmsten U, Andersson KE, Wingerup L. Treatment of premature labor with the calcium antagonist nifedipine. Arch Gynecol. 1980; 229(1): 1–5.
- Roos C, Spaanderman MEA, Schuit E, et al. APOSTEL-II Study Group. Effect of maintenance tocolysis with nifedipine in threatened preterm labor on perinatal outcomes: a randomized controlled trial. JAMA. 2013; 309(1): 41–47.
- Parry E, Roos C, Stone P, et al. The NIFTY study: a multicentre randomised double-blind placebo-controlled trial of nifedipine maintenance tocolysis in fetal fibronectin-positive women in threatened preterm labour. Aust N Z J Obstet Gynaecol. 2014; 54(3): 231–236.
- Aggarwal A, Bagga R, Girish B, et al. Effect of maintenance tocolysis with nifedipine in established preterm labour on pregnancy prolongation and neonatal outcome. J Obstet Gynaecol. 2018; 38(2): 177–184.
- Gaunekar NN, Crowther CA. Maintenance therapy with calcium channel blockers for preventing preterm birth after threatened preterm labour. Cochrane Database Syst Rev. 2004(3): CD004071.
- Magee LA, Schick B, Donnenfeld AE, et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol. 1996; 174(3): 823–828.
- Sørensen HT, Steffensen FH, Olesen C, et al. Pregnancy outcome in women exposed to calcium channel blockers. Reprod Toxicol. 1998; 12(3): 383–384.
- Blea CW, Barnard JM, Magness RR, et al. Effect of nifedipine on fetal and maternal hemodynamics and blood gases in the pregnant ewe. Am J Obstet Gynecol. 1997; 176(4): 922–930.
- Ferguson JE, Schutz T, Pershe R, et al. Nifedipine pharmacokinetics during preterm labor tocolysis. Am J Obstet Gynecol. 1989; 161(6 Pt 1): 1485–1490.
- Csapo AI, Puri CP, Tarro S, et al. Deactivation of the uterus during normal and premature labor by the calcium antagonist nicardipine. Am J Obstet Gynecol. 1982; 142(5): 483–491.
- Richichi J, Vasilenko P. The effects of nifedipine on pregnancy outcome and morphology of the placenta, uterus, and cervix during late pregnancy in the rat. Am J Obstet Gynecol. 1992; 167(3): 797–803.
- Parisi VM, Salinas J, Stockmar EJ. Fetal vascular responses to maternal nicardipine administration in the hypertensive ewe. Am J Obstet Gynecol. 1989; 161(4): 1035–1039.
- Impey L. Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. Br J Obstet Gynaecol. 1993; 100(10): 959–961.
- van Veen AJ, Pelinck MJ, van Pampus MG, et al. Severe hypotension and fetal death due to tocolysis with nifedipine. BJOG. 2005; 112(4): 509–510.
- Ahokas RA, Sibai BM, Mabie WC, et al. Nifedipine does not adversely affect uteroplacental blood flow in the hypertensive term-pregnant rat. American Journal of Obstetrics and Gynecology. 1988; 159(6): 1440–1445.
- Karahanoglu E, Altinboga O, Akpinar F, et al. Nifedipine increases fetoplacental perfusion. J Perinat Med. 2017; 45(1): 51–55.
